drugset / Trial / NCT02521649
Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer
Phase 2
Completed
52 enrolled
Cancer Advances Inc.
Clinical Project Services · collabMPS Research Unit · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
An open, dose-ranging, multiple dose, multi-centre study in patients with Stage I-III or Stage IV gastric cancer. Twelve patients in each of 5 treatment groups were to receive three injections at weeks 0, 2 and 6 with provision for a single booster injection in an extension study period.
Timeline
- Start
- 1998-09
- Primary completion
- 2001-01
- Completion
- 2001-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | G17DT Immunogen | Vaccine | 10 ug | — |
| Subject | G17DT Immunogen | Vaccine | 100 ug | — |
| Subject | G17DT Immunogen | Vaccine | 250 ug | — |